Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Education Program for Xarelto Adherence in Atrial Fibrillation
NCT02422602Completed
- Sponsor
- CHU Montpellier
- Start
- Nov 2013
- Primary completion
- May 2015
- Countries
- 1
01
Overview
Randomised, single-blind trial in Atrial fibrillation (AFib), sponsored by CHU Montpellier. Primary endpoint: The occurrence of serious adverse event at 12 months. Started Nov 2013; status: completed.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02422602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422602.